USFDA approves Pfizer’s Litfulo for adults and adolescents with severe alopecia areata
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
The company will submit its comprehensive response on these observations to the USFDA
The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India
Antimicrobial Resistance (AMR) poses a significant threat to global healthcare systems and patient safety
The company will supply materials to all global regions including Asia such as China, India, Europe, and the U.S.
This partnership will revolutionize Pharmarack's digital infrastructure with Snowflake's single, integrated platform to facilitate advanced analytic
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence
Subscribe To Our Newsletter & Stay Updated